ChemoCentryx (CCXI) Reports In-Line Q4 EPS

ChemoCentryx (NASDAQ: CCXI) reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $2.3 million versus the consensus estimate of $4.22 million.

For earnings history and earnings-related data on ChemoCentryx (CCXI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49